Summary:
Phase III, open label study of efficacy and safety of an investigational medication in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea.
Qualified Participants Must:
• Be diagnosed with Polycythemia Vera
•
Be resistant to or intolerant of hyroxyurea
•
Require phlebotomy due to inadequate hematocrit control at least once every 3 months
•
Palpable splenomegaly
•
Have elevated white blood cell and/or platelet counts
Qualified Participants May Receive:
All study related medication and care at no cost. Eligible participants will be compensated for time and travel.